Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Vaccine. 2016 Dec 22;35(5):831–841. doi: 10.1016/j.vaccine.2016.12.026

Table 1.

Clinical characteristics and baseline immune parameters

HIV−
responder
(n = 7)
HIV−
non-responder
(n = 9)
P value
HIV−
HIV+
responder
(n = 9)
HIV+
non-responder
(n = 17)
P value
HIV+
Age 38 (31–51) 38 (31–51) 0.59 39 (31–44 46 (36–55) 0.23
Sex (male/female) 4/3 (57%) 2/7 (22%) 0.30 6/3 (67%) 11/6 (65%) 0.99
CD4+ T cell counts 722 (485–970) 759 (459–1010) > 0.99 577 (476–791) 561 (442–751) 0.95
Co-infection with HCV 1 1
Infection duration
  2–5 years 4 1
  5–10 years 1 2
  > 10 years 4 14
Nadir CD4+ T cell counts 361 (221–454) 261 (163–464) 0.59

Data are medians (interquartile ranges)

P value: comparisons of P value between responders and non-responders